Skip to main content

Lung Transplant clinical trials at UCSF

7 in progress, 4 open to eligible people

Showing trials for
  • Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

    open to eligible people ages 18 years and up

    The objective of the trial is to assess efficacy and safety of add-on aerosolized liposomal cyclosporine A (L-CsA) to Standard of Care (SoC) therapy as compared to SoC therapy alone in the treatment of Bronchiolitis obliterans syndrome (BOS) in single lung transplant recipients.

    San Francisco, California and other locations

  • Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)

    open to eligible people ages 18 years and up

    The objective of the trial is to assess efficacy and safety of add-on aerosolized liposomal cyclosporine A (L-CsA) to Standard of Care (SoC) therapy as compared to SoC therapy alone in the treatment of Bronchiolitis obliterans syndrome (BOS) in double lung transplant recipients.

    San Francisco, California and other locations

  • Inhaled Sirolimus in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to learn about the safety and effectiveness of inhaled sirolimus in patients who have developed bronchiolitis obliterans syndrome (BOS), a form of chronic rejection, after lung transplantation. The main questions it aims to answer are: - Is inhaled sirolimus safe in these patients? - Is inhaled sirolimus effective in slowing BOS progression? Participants will: - Be randomly assigned to inhale either sirolimus or placebo (a look-alike substance that contains no active drug) daily for 48 weeks - Attend 10 study visits (mixture of in-person and telehealth) over the 48 week period - Undergo pulmonary function testing, bronchoscopy, lab testing, and physical examination - Submit weekly home spirometry monitoring Researchers will compare participants assigned to inhaled sirolimus versus placebo to see if sirolimus is safely tolerated and to assess the effectiveness of inhaled sirolimus on slowing BOS progression.

    San Francisco, California

  • OCS™ Lung TOP Registry For Donor Lungs for Transplantation

    open to eligible people ages 18 years and up

    Single-arm, prospective, multi-center, post-approval U.S. registry

    San Francisco, California and other locations

  • Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)

    Sorry, accepting new patients by invitation only

    The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.

    San Francisco, California and other locations

  • AlloSure Lung Assessment and Metagenomics Outcomes Study

    Sorry, not currently recruiting here

    ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, AlloID™, iBox, HistoMap, and AlloHeme) for surveillance post-transplant. This study aims to investigate the clinical utility of AlloSure®-Lung for surveillance of the spectrum of rejection and infection events in concert with standard of practice (SOP) post-transplant medical care in a robust lung transplant population. The AlloID™ metagenomics NGS plasma test will be collected and performed for research to validate this molecular diagnostic tool versus SOP microbiologic techniques for detection of allograft infection events.

    San Francisco, California and other locations

  • Long Term Follow up of the LTOG Cohort

    Sorry, accepting new patients by invitation only

    The purpose of the study is to follow participants who enrolled in the Lung Transplant Outcomes Group. Clinical data, functional assessments, and surveys will be collected to determine long term graft function and functional status of lung transplant recipients.

    San Francisco, California and other locations

Our lead scientists for Lung Transplant research studies include .

Last updated: